ADPTAdaptive Biotechnologies Corp
Earnings
When Adaptive Biotechnologies Corp reports, what it reported each quarter, and how the stock took the results.
34 quarters. Jun 30, 2018 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Feb 4, after the close
Thu, Feb 4, 2027in 78 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 12 – Mar 4
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $71.68M
- Revenue, change from a year earlier: Q3 2026 −10.7%, Q2 2026 +21.5%, Q1 2026 +35.1%, Q4 2025 +51.0%
- Net income
- -$13.58M
- Net income, change from a year earlier: Q3 2026 −69.9%, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 −66.7%, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $83.90M
- −10.7%
- Net income
- $2.88M
- −69.9%
- EPS
- $0.02
- −66.7%
- Revenue
- $71.55M
- +21.5%
- Net income
- -$39.79M
- N/M
- EPS
- -$0.25
- N/M
- Revenue
- $70.87M
- +35.1%
- Net income
- -$20.03M
- N/M
- EPS
- -$0.13
- N/M
- Revenue
- $71.68M
- +51.0%
- Net income
- -$13.58M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 4, 2026 · after-hours | Nov 4, 2026 | 35 d | 10-Q | $83.90M | −10.7% | $0.02 | +0.2% | |
| Q2 2026 | Jun 30, 2026 | Jul 29, 2026 · after-hours | Aug 4, 2026 | 35 d | 10-Q | $71.55M | +21.5% | -$0.25 | +7.0% | |
| Q1 2026 | Mar 31, 2026 | May 5, 2026 · after-hours | May 5, 2026 | 35 d | 10-Q | $70.87M | +35.1% | -$0.13 | +4.6% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Feb 5, 2026 · after-hours | Feb 26, 2026 | 57 d | 10-K | $71.68M | +51.0% | — | 4.2% | |
| Q3 2025 | Sep 30, 2025 | Nov 5, 2025 · after-hours | Nov 5, 2025 | 36 d | 10-Q | $93.97M | +102.4% | $0.06 | 11.5% | |
| Q2 2025 | Jun 30, 2025 | Aug 5, 2025 · after-hours | Aug 5, 2025 | 36 d | 10-Q | $58.88M | +36.3% | -$0.17 | +6.1% | |
| Q1 2025 | Mar 31, 2025 | May 1, 2025 · after-hours | May 1, 2025 | 31 d | 10-Q | $52.44M | +25.2% | -$0.20 | +34.0% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Feb 11, 2025 · after-hours | Mar 3, 2025 | 62 d | 10-K | $47.46M | +3.7% | — | 3.2% | |
| Q3 2024 | Sep 30, 2024 | Nov 7, 2024 · after-hours | Nov 7, 2024 | 38 d | 10-Q | $46.44M | +22.5% | -$0.22 | +3.6% | |
| Q2 2024 | Jun 30, 2024 | Aug 1, 2024 · after-hours | Aug 1, 2024 | 32 d | 10-Q | $43.19M | −11.7% | -$0.31 | 5.5% | |
| Q1 2024 | Mar 31, 2024 | May 7, 2024 · after-hours | May 7, 2024 | 37 d | 10-Q | $41.87M | +11.2% | -$0.33 | +14.5% | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Feb 14, 2024 · after-hours | Feb 29, 2024 | 60 d | 10-K | $45.78M | −17.1% | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 9, 2023 · after-hours | Nov 9, 2023 | 40 d | 10-Q | $37.92M | −20.7% | -$0.35 | — | |
| Q2 2023 | Jun 30, 2023 | Aug 2, 2023 · after-hours | Aug 2, 2023 | 33 d | 10-Q | $48.93M | +12.1% | -$0.33 | — | |
| Q1 2023 | Mar 31, 2023 | May 3, 2023 · after-hours | May 3, 2023 | 33 d | 10-Q | $37.65M | −2.5% | -$0.40 | 7.6% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Feb 14, 2023 · after-hours | Feb 14, 2023 | 45 d | 10-K | $55.20M | +45.5% | — | — | |
| Q3 2022 | Sep 30, 2022 | Nov 3, 2022 · after-hours | Nov 3, 2022 | 34 d | 10-Q | $47.83M | +21.2% | -$0.32 | +13.2% | |
| Q2 2022 | Jun 30, 2022 | Aug 3, 2022 · after-hours | Aug 3, 2022 | 34 d | 10-Q | $43.66M | +13.4% | -$0.37 | — | |
| Q1 2022 | Mar 31, 2022 | May 4, 2022 · after-hours | May 4, 2022 | 34 d | 10-Q | $38.62M | +0.5% | -$0.44 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Feb 15, 2022 · after-hours | Feb 15, 2022 | 46 d | 10-K | $37.93M | +25.7% | — | 2.8% | |
| Q3 2021 | Sep 30, 2021 | Nov 3, 2021 · after-hours | Nov 3, 2021 | 34 d | 10-Q | $39.47M | +50.1% | -$0.40 | — | |
| Q2 2021 | Jun 30, 2021 | Aug 4, 2021 · after-hours | Aug 4, 2021 | 35 d | 10-Q | $38.51M | +83.5% | -$0.35 | +0.9% | |
| Q1 2021 | Mar 31, 2021 | May 5, 2021 · after-hours | May 5, 2021 | 35 d | 10-Q | $38.44M | +83.8% | -$0.29 | +3.2% | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | Feb 24, 2021 · after-hours | Feb 24, 2021 | 55 d | 10-K | $30.19M | +24.7% | — | 3.1% | |
| Q3 2020 | Sep 30, 2020 | Nov 10, 2020 · after-hours | Nov 10, 2020 | 41 d | 10-Q | $26.30M | +0.9% | -$0.27 | — | |
| Q2 2020 | Jun 30, 2020 | Aug 10, 2020 · after-hours | Aug 10, 2020 | 41 d | 10-Q | $20.99M | −5.2% | -$0.26 | 1.5% | |
| Q1 2020 | Mar 31, 2020 | May 12, 2020 · after-hours | May 12, 2020 | 42 d | 10-Q | $20.91M | +65.1% | -$0.25 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | Feb 26, 2020 · after-hours | Feb 26, 2020 | 57 d | 10-K | $24.21M | — | — | 5.2% | |
| Q3 2019 | Sep 30, 2019 | Nov 12, 2019 · after-hours | Nov 12, 2019 | 43 d | 10-Q | $26.06M | +51.6% | -$0.11 | 3.8% | |
| Q2 2019 | Jun 30, 2019 | Aug 13, 2019 · after-hours | Aug 13, 2019 | 44 d | 10-Q | $22.14M | +91.4% | -$1.23 | +9.7% | |
| Q1 2019 | Mar 31, 2019 | — | — | — | — | $12.67M | — | -$1.45 | — | |
| FY 2018 | ||||||||||
| Q4 2018derived | Dec 31, 2018 | — | — | — | — | — | — | — | — | |
| Q3 2018 | Sep 30, 2018 | — | — | — | — | $17.19M | — | -$0.66 | — | |
| Q2 2018 | Jun 30, 2018 | — | — | — | — | $11.57M | — | -$1.01 | — | |
Earlier years, FY 2018 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Adaptive Biotechnologies Corp · CIK 1478320 · Engraved from SEC EDGAR